Precigen, Inc. Cost of Revenue

Cost of Revenue of PGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending September 29, 2021 was $15.5 Million (a 2.77% increase compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue increased by 12.04%
  • Annual Cost of Revenue for 2020 was $55.5 Million (a -9.59% decrease from previous year)
  • Annual Cost of Revenue for 2019 was $61.4 Million (a -2.03% decrease from previous year)
  • Annual Cost of Revenue for 2018 was $62.7 Million (a -0.18% decrease from previous year)
  • Twelve month Cost of Revenue ending September 29, 2021 was $57.2 Million (a 4.12% increase compared to previous quarter)
  • Twelve month trailing Cost of Revenue increased by 3.13% year-over-year
Trailing Cost of Revenue for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$57.2 Million $55 Million $54.9 Million $55.5 Million
Visit stockrow.com/PGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of Precigen, Inc.

Most recent Cost of Revenueof PGEN including historical data for past 10 years.

Interactive Chart of Cost of Revenue of Precigen, Inc.

Precigen, Inc. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $15.45 $15.03 $12.98
2020 $13.79 $13.19 $14.91 $13.63 $55.51
2019 $15.41 $14.46 $16.72 $14.81 $61.4
2018 $13.5 $15.33 $18.53 $15.31 $62.68
2017 $14.02 $15.01 $16.85 $15.81 $62.79
2016 $14.36 $14.96 $17.09 $15.23 $61.64
2015 $14.96 $16.67 $18.27 $14.04 $63.93
2014 $12.63 $6.54 $0.05 $0.03 $19.26
2013 $0.02

Business Profile of Precigen, Inc.

Sector: Healthcare
Industry: Biotechnology
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.